Print

Cenix BioScience GmbH and CellCentric Ltd. Second RNAi-Based Target Validation Project  
7/1/2008 2:10:33 PM

Dresden, Germany, July 1, 2008 – Cenix BioScience GmbH (Dresden), the leading specialist in advanced RNA interference (RNAi)-based research services, today announced that it has initiated a second target validation project under the framework research agreement signed previously with UK-based CellCentric Ltd, a biotechnology company developing therapeutics against a series of novel epigenetic targets.

The new project follows the success of the parties’ initial pilot together, wherein candidate drug targets chosen by CellCentric for their high therapeutic anti-cancer potential, were subjected by Cenix to RNAi-based phenotypic characterization using multi-parametric microscopy assays in a diverse panel of human cell lines.

Cenix will now apply the same combination of high throughput RNAi with own proprietary high content assays using the Definiens® Cellenger™ image analysis platform, to generate a detailed characterization of loss-of-function phenotypes for several more oncology target candidates across a new collection of human cell lines.

“The relationship with Cenix has been highly productive and we are pleased to be expanding the relationship to cover further novel epigenetic targets. We have been impressed both with the quality of the work conducted and the detailed reporting of results.” noted Will West, CEO of CellCentric.

“We at Cenix feel very gratified that the first dataset we delivered for the pilot study has already proven useful in driving forward the CellCentric oncology program,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “We therefore very much look forward to continuing this exciting and productive relationship through this second project”.

About Cenix BioScience GmbH Cenix BioScience GmbH is a pioneer and global leader in the convergence of high throughput (HT), genomics-driven applications of RNA interference (RNAi) with high content, multi-parametric cell-based assays. Founded in 1999 as the first biotechnology company specializing in HT-RNAi, Cenix has accumulated unparalleled depth and breadth of experience in this field, using human and rodent cell models in a wide range of disease indications, including oncology, atherosclerosis, diabetes, obesity, neurodegenerative disorders and infectious diseases such as malaria. Cenix offers its unique expertise to industry and academic researchers through fully customizable research and consulting services, focusing on the discovery and validation of novel therapeutic drug targets and the analysis of drug mechanisms of action. Please contact Cenix or visit the company’s web site www.cenix-bioscience.com for more information.

About CellCentric Ltd. CellCentric is a biotechnology company focused on epigenetics. From a worldwide network of over 20 leading laboratories and Institutions in the space, the company identifies, prioritises and develops novel epigenetic targets, assays and tools. For further information see: www.cellcentric.com

Contact, Cenix: Birte Sönnichsen, COO Cenix BioScience GmbH Tel: +49 (0) 351 4173-0 Email:soennichsen@cenix-bioscience.com

Contact, CellCentric: Will West CellCentric Ltd. Tel: +44 1799 531 130 Email: Will.West@cellcentric.com

//-->